tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kevin Fischbeck, 32 are a SELL (13.97%), 120 are a BUY (52.4%), 77 are a HOLD (33.62%).
Analyst Kevin Fischbeck, currently employed at BAML, carries an average stock price target met ratio of 71.54% that have a potential upside of 24.6% achieved within 265 days.
Kevin Fischbeck’s has documented 447 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on HUM, Humana at 29-Jul-2026.
Analyst best performing recommendations are on CLOV (CLOVER HEALTH INVESTMENTS CORP).
The best stock recommendation documented was for HUM (HUMANA) at 6/24/2026. The price target of $380 was fulfilled within 2 days with a profit of $19.21 (5.32%) receiving and performance score of 26.62.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 05-Dec-2025
$125
$40.86 (48.56%)
$22
18 days ago
(15-Sep-2026)
2/5 (40%)
$32.88 (35.69%)
34
Sell Since 24-Aug-2026
$85
$0.86 (1.02%)
1 months 9 days ago
(24-Aug-2026)
2/2 (100%)
$-8.79 (-9.37%)
34
Sell Since 11-Aug-2026
$115
$30.86 (36.68%)
$105
1 months 22 days ago
(11-Aug-2026)
7/8 (87.5%)
$28.61 (33.12%)
50
Buy Since 10-May-2021
$146
$61.86 (73.52%)
$141
1 months 22 days ago
(11-Aug-2026)
7/10 (70%)
$59.61 (69.00%)
89
Hold Since 06-Aug-2026
$111
$26.86 (31.92%)
$81
1 months 27 days ago
(06-Aug-2026)
2/3 (66.67%)
$24.17 (27.84%)
61
Which stock is Kevin Fischbeck most bullish on?
Which stock is Kevin Fischbeck most reserved on?
What Year was the first public recommendation made by Kevin Fischbeck?
